Vol. 7, Issue 1, Part A (2025)

Background: Anemia frequently complicates chronic kidney disease (CKD) due to decreased erythropoietin production, iron deficiency, and chronic inflammation. It increases morbidity, and cardiovascular risks while reducing the quality of life of patients. Its prevalence varies by disease severity and healthcare access. Assessing its burden is crucial for early diagnosis and effective management in CKD patients. This study aimed to assess the prevalence of anemia in chronic kidney disease patients.
Methods: This hospital-based cross-sectional study was conducted at the Department of Nephrology, Aichi Medical College and Hospital, Dhaka, Bangladesh, from January 2023 to December 2024. A total of 217 CKD patients were enrolled using a purposive sampling technique. Hematological examinations, including hemoglobin level assessment, were performed to detect anemia. Demographic and clinical characteristics of the participants were documented using a predesigned questionnaire. Data were analyzed using MS Office tools.
Results: Anemia prevalence was 41%, with similar rates in both genders. It was more common in urban (57.4%) than rural (26.7%) residents and highest in high-income individuals (47.1%). Former smokers (43.7%) had slightly higher anemia rates than never-smokers (43.2%), while current smokers had the lowest (26.5%). Anemia increased with CKD severity (7.4% in stage 1 to 86.7% in stage 5) and comorbidity severity (71.4% in very high-index patients).
Conclusion: Anemia is a prevalent complication in chronic kidney disease, increasing with disease progression and comorbidity severity. Early screening and targeted management are essential to reduce its burden, enhance patient outcomes, and improve the quality of life in affected individuals.